Those who have served in the military are about twice as likely to develop ALS as those who have not served.2,3
Enroll in the ALS Care Locator
MEDICAL PRACTICERADICAVA ORS® recognized as a MAJOR CONTRIBUTION TO PATIENT CARE by the FDA.1 Request a rep visit.
Actor portrayals.
Those who have served in the military are about twice as likely to develop ALS as those who have not served.2,3
Recognizes ALS as a service-connected disease and provide medical and financial support to those with at least 90 continuous days of military service3,4,b (see footnote)
Provides resources, education, and support to caregivers of veterans5
Provides access to treatment for ALS, including RADICAVA (edaravone)®1
Offers some benefits to a veteran's spouse or children, even if the veteran has passed away due to ALS6
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
For unknown reasons, military veterans are twice as likely to be diagnosed with ALS than the general public. The addition of RADICAVA ORS® (edaravone) to the VA National Formulary symbolizes not only the dedication and recognition of veterans by MTPA and the VA, but also a significant step forward for those in the ALS community in need of an alternate treatment option.
Disability compensation benefits are based on disability rating and dependent family members.8
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
They can check with their local VHA enrollment center or military treatment facility DEERS office for more information.6,7,9-11
My patient is not currently enrolled in the VHA healthcare system and they may still qualify for ALS treatment through the VHA.15
To get started with the VHA, they can apply15:
ONLINE at VA.gov
BY CALLING 1-877-222-VETS (1-877-222-8387)
IN PERSON at their local VA medical facility
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
If the veteran is separating from service due to a service-connected illness,
they may be eligible for VA healthcare benefits and certain TRICARE benefits.16
Please contact your Mitsubishi Tanabe Pharma America Manager of Patient Access or Federal Account Manager for more information.
aSubject to National Prior Authorization criteria. Return to content
bA service connection for ALS for any veteran who develops the disease at any time after separation from service. Return to content
cTo be eligible for treatment with RADICAVA® IV or RADICAVA ORS®, veterans must be enrolled in the federal program. Return to content
dFor illustrative purposes only. Return to content
VA=Veterans Affairs; VHA=Veterans Health Administration.
DEERS=Defense Enrollment Eligibility Reporting System.
MTF=Military Treatment Facility.
References: 1. US Department of Veterans Affairs. Pharmacy benefits management services. https://www.pbm.va.gov/apps/VANationalFormulary/. Accessed October 12, 2020.
2. VA improves quality of care for veterans diagnosed with ALS. News release. US Department of Veterans Affairs. October 13, 2021. Accessed October 25, 2022. https://www.va.gov/opa/pressrel/pressrelease.cfm?id=5727 3. US Department of Veterans Affairs. Quality of care: ALS disease awareness month. https://www.va.gov/QUALITYOFCARE/ education/ALS_Disease_Awareness_Month.asp. Accessed October 12, 2020. 4. US Department of Veterans Affairs. Federal Benefits for Veterans, Dependents and Survivors. Washington, DC: US Department of Veterans Affairs; 2019. https://www.va.gov/opa/publications/benefits_book/2019_Federal_Benefits_for_ Veterans_Dependents_and_survivors.pdf. Accessed October 12, 2020. 5. US Department of Veterans Affairs. VA caregiver support. https://www.caregiver.va.gov/ Care_Caregivers.asp. Accessed October 12, 2020. 6. US Department of Veterans Affairs. Dependency and indemnity compensation. https://benefits.va.gov/ BENEFITS/ factsheets/survivors/dic.pdf. Accessed October 12, 2020. 7. VA makes specially adaptive housing grant eligibility automatic for veterans and servicemembers living with ALS. [news release]. Washington, DC: US Department of Veterans Affairs; March 19, 2014. https://www.va.gov/opa/pressrel/ pressrelease.cfm?id=2530. Accessed October 12, 2020. 8. US Department of Veterans Affairs. 2020 Veterans disability compensation rates. https://www.va. gov/disability/compensation-rates/veteran-rates/. Accessed October 12, 2020. 9. US Department of Veterans Affairs. Special claims. https://www.va.gov/disability/ eligibility/specialclaims/. Accessed October 12, 2020. 10. US Department of Veterans Affairs. Automobile and special adaptive equipment grants. https://benefits. va.gov/BENEFITS/factsheets/serviceconnected/Auto.pdf. Accessed October 12, 2020. 11. US Department of Veterans Affairs. Specially adapted housing program. https://benefits.va.gov/BENEFITS/factsheets/homeloans/SAHFactsheet.pdf. Accessed October 12, 2020. 12. US Department of Veterans Affairs. VHA Handbook 1101.07: Amyotropic (sic) Lateral Sclerosis (ALS) System of Care Procedures. https://www.va.gov/vhapublications/ ViewPublication.asp?pub_ID=3014. Published July 7, 2014. Accessed October 12, 2020. 13. TRICARE. Life events: retiring from active duty. https://www.tricare.mil/ LifeEvents/InjuredonAD/TransitionVA/Retiring. Accessed October 12, 2020. 14. TRICARE. Contact us. https://tricare.mil/ContactUs/CallUs. Accessed October 12, 2020. 15. US Department of Veterans Affairs. How to apply for VA health care. https://www.va.gov/health-care/how-to-apply/. Accessed October 12, 2020. 16. US Department of Veterans Affairs. Eligibility for VA health care. https://www.va.gov/health-care/eligibility/. Accessed October 12, 2020.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.